Wedbush Reiterates Neutral Rating on NovoCure Limited (NVCR)

Market Context

NovoCure Limited operates in the Healthcare sector. The stock currently trades at $18.22 with a market capitalization of $1.5B.

Analyst coverage from Wedbush provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for NovoCure Limited.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for NovoCure Limited

Among the 10 most recent ratings: 5 Buy, 5 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 24, 2026	Wedbush	Neutral	N/A
Jul 23, 2026	HC Wainwright & Co.	Buy	N/A
Jul 13, 2026	JP Morgan	Neutral	N/A
Jun 18, 2026	HC Wainwright & Co.	Buy	N/A
May 04, 2026	Wells Fargo	Equal-Weight	N/A

Related Tools: Analyst Ratings Dashboard | View NVCR Stock Page